Evidence map›Paper›PMID 28958854›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2017

Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.

Feihu Wang, Michael Porter, Alexandros Konstantopoulos, Pengcheng Zhang, Honggang Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 185 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. A Patent Analysis on Nano Drug Delivery Systems.Recent patents on nanotechnology · 2025
    Review
  19. Review
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Feihu WangDepartment of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States.
Michael PorterDepartment of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States.
Alexandros KonstantopoulosDepartment of Biomedical Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States.
Pengcheng ZhangDepartment of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States.
Honggang CuiDepartment of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States; Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, MD 21231, United States; Institute for NanoBiotechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States. Electronic address: hcui6@jhu.edu.
Johns Hopkins University · US

Funding

Camptothecin Transformative Nanotubes as Effective Drug CarriersR21CA191740 · NCI · JOHNS HOPKINS UNIVERSITY · PI CUI, HONGGANG · 2015 to 2016
$377k
NCI NIH HHS R21 CA191740
6 · The paper itself

Abstract

Paclitaxel (PTX) is one of the most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer types. Formulating PTX with Cremophor EL and ethanol (Taxol®) realized its clinical potential, but the formulation falls short of expectations due to side effects such as peripheral neuropathy, hypotension, and hypersensitivity. Abraxane®, the albumin bound PTX, represents a superior replacement of Taxol® that mitigates the side effects associated with Cremophor EL. While Abraxane® is now considered a gold standard in chemotherapy, its 21% response rate leaves much room for further improvement. The quest for safer and more effective cancer treatments has led to the development of a plethora of innovative PTX formulations, many of which are currently undergoing clinical trials. In this context, we review recent development of PTX drug delivery systems and analyze the design principles underpinning each delivery strategy. We chose several representative examples to highlight the opportunities and challenges of polymeric systems, lipid-based formulations, as well as prodrug strategies.

Indexed as

Drug Delivery SystemsAnimalsAntineoplastic Agents, PhytogenicHumansLipidsNanoparticlesNeoplasmsPaclitaxelPolymersProdrugsAntineoplastic Agents, PhytogenicLipidsPaclitaxelPolymersProdrugsCancerChemotherapyDrug deliveryNanomedicinePaclitaxel

Identifiers

PMID28958854
PMCPMC5723209
OpenAlexW2758199728

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.